Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEC-C and Venetoclax for Relapsed AML After Stem Cell Transplant
NCT05799079Phase 2Terminated
- Start
- Apr 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, cedazuridine, venetoclax in acute myeloid leukemia (AML). Started Apr 2023; status: terminated.
02
Drugs
decitabinecedazuridinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05799079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799079.